6 Houston health tech startups making major advancements right now

meet the finalists

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health. Photo courtesy Koda Health.

Home to leading hospitals, universities and health-focused incubators, Houston is a breeding ground for innovative medical technology and breakthroughs that can improve outcomes and lead to a better quality of life for patients.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Six forward-thinking businesses have been named finalists for the 2025 award. They range from an end-of-life care company to others developing devices and systems for heart monitoring, sleep apnea, hearing loss and more.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled at our live awards ceremony.

Tickets are now on sale for this exclusive event celebrating all things Houston Innovation.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient. The system is currently in the research and development phase and is being used in clinical trials and studies.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. It raised a pre-seed round last year of $435,000.

Corveus Medical

Corveus Medical has developed a novel catheter device that allows cardiologists to perform a splanchnic nerve ablation, restoring the pressure balance in patients with moderate heart failure. Its pre-FDA-approved, minimally invasive solution deactivates a nerve that has been demonstrated to be a root cause behind heart failure progression, which allows physicians to treat patients who have traditionally had few options.

The company, formerly known as Caridian Medical, was founded in 2021 by CEO Tyler Melton and CMO Ishan Kamat. It has participated in incubators such as TMC Biodesign, Y Combinator, MedTech Innovator and Fogarty Innovation and was named one of the 10 most promising life science companies at Texas Life Science Forum in 2022. The company says it will move toward validation and verification testing for its device in Q4 of this year.

FibroBiologics

Regenerative medicine company FibroBioligics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells to repair tissue and modulate the immune system. The cell therapies offer treatments for chronic conditions such as degenerative disc disease, multiple sclerosis and non-healing wounds.

The publicly traded company was founded in 2021 by CEO Pete O'Heeron. It opened a new 10,000-square-foot Houston lab earlier this year to scale up research efforts and pave the way for in-house manufacturing. The company says it plans to launch its first clinical trial for diabetic foot ulcers soon, representing the transition of its fibroblast technology to the clinic setting.

Koda Health

Koda Health has developed an advance care planning platform (ACP) that allows users to document and share their care preferences, goals and advance directives for health systems. The web-based platform guides patients through values-based decisions with interactive tools and generates state-specific, legally compliant documents that integrate seamlessly with electronic health record systems. The company also added kidney action planning to its suite of services for patients with serious illnesses last year.

Koda Health was founded out of the TMC's Biodesign Fellowship in 2020 by CEO Tatiana Fofanova, chief medical officer Dr. Desh Mohan, and chief technology officer Katelin Cherry. The company raised a $7 million series A earlier this year, and also announced major partnerships and integrations with Epic, Guidehealth, Medical Home Network, Privia Health and others.

NanoEar

NanoEar has miniaturized hearing aid technology so that it can be implanted across the eardrum, allowing adults with age-related hearing loss to enjoy better sound quality than they would with behind-the-ear hearing aids.

Dr. Ron Moses, an ENT specialist and surgeon at Houston Methodist, developed the technology, and the company was founded in 2016 with CFO Willem Vermaat and COO Michael Moore. The company participated in the TMC Innovation Institute in 2016. It has issued nine U.S. patents and performed successful human cadaver and animal proof-of-concept experiments. Its next step is developing a prototype.

Wellysis USA

Wellysis USA Inc. works to detect heart rhythm disorders with its continuous ECG/EKG monitor with AI reporting. Its S-Patch cardiac monitor is designed for extended testing periods of up to 14 days on a single battery charge. The device weighs only 9 grams, is waterproof and designed to be comfortable to wear, and is considered to have a high detection rate for arrhythmias. It is ideally suited for patient-centric clinical trials to help physicians make diagnoses faster, cheaper and more conveniently.

It was established in Houston in 2023 and participated in the JLABS SFF Program the same year. It closed a $12 million series B last year. It was founded by CEO Young Juhn, CTO Rick Kim, CFO JungSoo Kim and chief strategy officer JoongWoo Kim.

---

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

From Your Site Articles
Three Houston-based health tech companies were announced to have joined the 2022 cohort of MedTech Innovator. Photo via Getty Images

3 Houston health tech companies join global accelerator cohort

Three Houston-based medtech startups are getting a big boost from a medtech accelerator.

The startups — Ad Vital, Corveus Medical, and CorInnova — have been chosen from this year’s cohort for MedTech Innovator, an international accelerator that helps companies that created health care technology. In all, 55 startups are involved in this year’s four-month accelerator program.

Ad Vital and Corveus Medical also are participating in MedTech Innovator’s corporate mentorship program, while CorInnova is one of five startups picked for the pediatric accelerator track.

MedTech Innovator’s 10th annual program kicked off in mid-June at the MedTech Innovator Summit in Mountain View, California. Leaders from each of the 50 startups attended networking events and workshops with MedTech Innovator partners and other industry professionals. Members of this year’s cohort also were featured June 17 at the WSGR Medical Device Conference in San Francisco.

Only 5 percent of applicants were accepted for this year’s accelerator program. Earlier this year, MedTech Innovator held in-person pitch events in five cities, including Houston.

At the conclusion of the 2022 program, MedTech Innovator will award $500,000 in cash and in-kind prizes at this October’s MedTech Conference in Boston. The grand prize is $350,000.

“Over the past nine years, MedTech Innovator has established a unique track record of identifying and supporting leading startups, with 95 percent of our graduates either still in business or having been acquired,” Paul Grand, CEO of MedTech Innovator, says in a news release.

Here’s an overview of what Ad Vital, Corveus Medical, and CorInnova do:

  • Ad Vital’s app helps medical practices through sales, marketing, and operations. For instance, the app automatically organizes sales campaigns aimed at converting customer leads via text messages, emails, and Facebook messages.
  • Corveus Medical’s catheter device is designed to prevent heart failure. More than 6 million American adults experience heart failure. The company is also among five selected to pitch in October for a competition from the National Capital Consortium for Pediatric Device Innovation.
  • CorInnova’s minimally invasive device is engineered to treat congestive heart failure, particularly infants. Each year, about 10,000 babies born in the U.S. have critical heart defects that often require surgery or other procedures.
Houston's medical innovation community congregated to discuss breakthrough innovations in health care. Photo via Getty Images

Houston organizations announce 10 most promising life science startups

future of health care

What startups are creating the future of health care? A Houston conference this week gathered to discuss.

The 10th annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship engaged thought leadership within the life science community with panels, discussions, and more. Additionally, 49 companies pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

Austin-based Dynamic Light won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The software company integrates with microscope or robotic systems to provide better visuals to surgeons and health care providers and reduce medical errors, radiation and costs. The award was presented by Ann Tanabe, CEO of BioHouston.

The event also named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

Ares Immunotherapy

Photo via Getty Images

Based in Cartersville, Georgia, Ares Immunotherapy uses a unique subset of T-cells for the treatment of solid tumors. According to the company, it is is preparing for a first in man trial in mesothelioma in 2023.

Corveus Medical

Photo courtesy of TMC

Houston-based Corveus Medical, which was formerly known as Caridian Medical, is a part of TMC's Biodesign program. The company was founded by Ishan Kamat, COO, and Tyler Melton, CEO.

"We are developing a novel, catheter-based device that performs a targeted sympathetic nerve ablation to treat heart failure," according to the company. "Our solution leverages the body’s natural mechanisms to bring fluid levels back to normal, giving physicians an effective treatment option, reducing costs for hospitals, and improving quality of life for the patient."

Drusolv Therapeutics

Photo via Pexels

Drusolv Therapeutics, based in Philadelphia, Pennsylvania, was founded out of Harvard University and been validated in a proof-of-concept clinical trial. The company's product, a novel reformulation of atorvastatin, is targeting age-related macular degeneration, or AMD, a serious eye disease. According to the company, it's a $4 billion a year, unmet need.

EMPIRI

Photo via jlabs.jnjinnovation.com

Houston-based EMPIRI is an early-stage biotechnology company currently focusing on precision oncology and utilizing automation for personal diagnosis. The company works out of JLABS @ TMC.

"Our proprietary 3D tissue culture method, E-slices, enables personalized drug response measurements from intact patient tissues," per the company. "E-slice has been clinically validated to accurately predict individual cancer patient responses to chemotherapies, targeted therapies, a immunotherapies."

Lapovations

Photo via Getty Images

Based in Fayetteville, Arkansas, Lapovations is working on technologies that improve laparoscopy.

"Our flagship product AbGrab is a single-use device that uses suction to lift the abdominal wall prior to closed insertion entry," according to the company. "Manually lifting can be difficult and unreliable, especially with obese patients or for clinicians with small hands."

Maxwell Biosciences

Photo by Chokniti Khongchum from Pexels

Austin-based Maxwell Biosciences is creating anti-infectives that inactivate a broad spectrum of viruses. The company's product, CLAROMERS, has seen success in its preclinical animal studies, as well as lab-grown human tissues. Maxwell is fueled by over $30 million in non-dilutive and government funding (e.g. DARPA, NIH, NIAID).

NeuraStasis

Image via neurastasis.com

Doctors have to respond quickly when treating ischemic stroke patients, and Houston-based NeuraStasis is working on a way to give them more time. Each minute a patient is waiting, irreparable damage is being done. The company's noninvasive solution uses electrical neurostimulation to preserve brain functionality. NeuraStasis is based in JLABS @ TMC.

Vena Medical

Image via venamed.ca

Canada medical device company Vena Medical is working on the "world's smallest camera" that is able to record inside veins and arteries to help physicians treat stroke.

Vivifi Medical

Photo courtesy of TMC

Houston-based Vivifi Medical, a Texas Medical Center Innovation company, is working to improve the quality of life of patients with Male Infertility and benign prostatic hyperplasia — 12 million men in the United States alone — by ending recurrency via suture-less laparoscopic technology.

XN Health

Image via xn-health.com

XN Health, based in Houston, has developed a novel approach to phrenic nerve stimulation to treat progression of ventilator induced diaphragm disfunction to help wean patients off the ventilator faster. The technology should speed up patient liberation times, shortening ICU stay, improve healthcare outcomes, and reduce health care costs.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston scores $120M in new cancer research and prevention grants

cancer funding

The Cancer Prevention and Research Institute of Texas has granted more than $120 million to Houston organizations and companies as part of 73 new awards issued statewide.

The funds are part of nearly $154 million approved by the CPRIT's governing board earlier this month, bringing the organization's total investment in cancer prevention and research to more than $4 billion since its inception.

“Today marks an important milestone for CPRIT and for every Texan affected by cancer,” CEO Kristen Doyle said in a news release. “Texas has invested $4 billion in the fight against one of the world’s greatest public health challenges. Over 16 years, that support has helped Texas lead the search for breakthrough treatments, develop new cancer-fighting drugs and devices, and—most importantly—save tens of thousands of lives through early cancer detection and prevention. Every Texan should know this effort matters, and we’re not finished yet. Together, we will conquer cancer.”

A portion of the funding will go toward recruiting leading cancer researchers to Houston. CPRIT granted $5 million to bring John Quackenbush to Baylor College of Medicine. Quackenbush comes from the Harvard T.H. Chan School of Public Health and is an expert in computational and systems biology. His research focuses on complex genomic data to understand cancer and develop targeted therapies.

The University of Texas M.D. Anderson Cancer Center also received $3 million to recruit Irfan Asangani, an associate professor at the University of Pennsylvania Perelman School of Medicine. His research focuses on how chromatin structure and epigenetic regulation drive the development and progression of cancer, especially prostate cancer.

Other funds will go towards research on a rare, aggressive kidney cancer that impacts children and young adults; screening programs for breast and cervical cancer; and diagnostic technology.

In total, cancer grants were given to:

  • The University of Texas M.D. Anderson Cancer Center: $29.02 million
  • Baylor College of Medicine: $15.04 million
  • The University of Texas Health Science Center at Houston: $9.37 million
  • Texas A&M University System Health Science Center: $1.2 million
  • University of Houston: $900,000

Additional Houston-based companies landed grants, including:

  • Crossbridge Bio Inc.: $15.01 million
  • OncoMAGNETx Inc.: $13.97 million
  • Immunogenesis Inc.: $10.85 million
  • Diakonos Oncology Corporation: $7.16 million
  • Iterion Therapeutics Inc.: $7.13 million
  • NovaScan Inc.: $3.7 million
  • EMPIRI Inc.: $2.59 million
  • Air Surgical Inc.: $2.58 million
  • Light and Salt Association: $2.45 million

See the full list of awards here.

U.S. News names 5 Houston suburbs as the best places to retire in 2026

Retirement Report

Houston-area suburbs should be on the lookout for an influx of retirees in 2026. A new study by U.S. News and World Report has declared The Woodlands and Spring as the fourth and fifth best cities to retire in America, with three other local cities making the top 25.

The annual report, called "250 Best Places to Retire in the U.S. in 2026" initially compared 850 U.S. cities, and narrowed the list down to a final 250 cities (up from 150 previously). Each locale was analyzed across six indexes: quality of life for individuals reaching retirement age, value (housing affordability and cost of living), health care quality, tax-friendliness for retirees, senior population and migration rates, and the strength of each city's job market.

Midland, Michigan was crowned the No. 1 best place to retire in 2026. The remaining cities that round out the top five are Weirton, West Virginia (No. 2) and Homosassa Springs, Florida (No. 3).

According to U.S. News, about 15 percent of The Woodlands' population is over the age of 65. The median household income in this suburb is $139,696, far above the national average median household income of $79,466.

Though The Woodlands has a higher cost of living than many other places in the country, the report maintains that the city "offers a higher value of living compared to similarly sized cities."

"If you want to buy a house in The Woodlands, the median home value is $474,279," the city's profile on U.S. News says. "And if you're a renter, you can expect the median rent here to be $1,449." For comparison, the report says the national average home value is $370,489.

Spring ranked as the fifth best place to retire in 2026, boasting a population of more than 68,000 residents, 11 percent of whom are seniors. This suburb is located less than 10 miles south of The Woodlands, while still being far enough away from Houston (about 25 miles) for seniors to escape big city life for the comfort of a smaller community.

"Retirees are prioritizing quality of life over affordability for the first time since the beginning of the COVID-19 pandemic," said U.S. News contributing editor Tim Smart in a press release.

The median home value in Spring is lower than the national average, at $251,247, making it one of the more affordable places to buy a home in the Houston area. Renters can expect to pay a median $1,326 in monthly rent, the report added.

Elsewhere in Houston, Pearland ranked as the 17th best place to retire for 2026, followed by Conroe (No. 20) and League City (No. 25).

Other Texas cities that ranked among the top 50 best places to retire nationwide include Victoria (No. 12), San Angelo (No. 28), and Flower Mound (No. 37).

The top 10 best U.S. cities to retire in 2026 are:

  • No. 1 – Midland, Michigan
  • No. 2 – Weirton, West Virginia
  • No. 3 – Homosassa Springs, Florida
  • No. 4 – The Woodlands, Texas
  • No. 5 – Spring, Texas
  • No. 6 – Rancho Rio, New Mexico
  • No. 7 – Spring Hill, Florida
  • No. 8 – Altoona, Pennsylvania
  • No. 9 – Palm Coast, Florida
  • No. 10 – Lynchburg, Virginia
---

This article originally appeared on CultureMap.com.

Micro-nuclear reactor to launch at Texas A&M innovation campus in 2026

nuclear pilot

The Texas A&M University System and Last Energy plan to launch a micro-nuclear reactor pilot project next summer at the Texas A&M-RELLIS technology and innovation campus in Bryan.

Washington, D.C.-based Last Energy will build a 5-megawatt reactor that’s a scaled-down version of its 20-megawatt reactor. The micro-reactor initially will aim to demonstrate safety and stability, and test the ability to generate electricity for the grid.

The U.S. Department of Energy (DOE) fast-tracked the project under its New Reactor Pilot Program. The project will mark Last Energy’s first installation of a nuclear reactor in the U.S.

Private funds are paying for the project, which Robert Albritton, chairman of the Texas A&M system’s board of regents, said is “an example of what’s possible when we try to meet the needs of the state and tap into the latest technologies.”

Glenn Hegar, chancellor of the Texas A&M system, said the 5-megawatt reactor is the kind of project the system had in mind when it built the 2,400-acre Texas A&M-RELLIS campus.

The project is “bold, it’s forward-looking, and it brings together private innovation and public research to solve today’s energy challenges,” Hegar said.

As it gears up to build the reactor, Last Energy has secured a land lease at Texas A&M-RELLIS, obtained uranium fuel, and signed an agreement with DOE. Founder and CEO Bret Kugelmass said the project will usher in “the next atomic era.”

In February, John Sharp, chancellor of Texas A&M’s flagship campus, said the university had offered land at Texas A&M-RELLIS to four companies to build small modular nuclear reactors. Power generated by reactors at Texas A&M-RELLIS may someday be supplied to the Electric Reliability Council of Texas (ERCOT) grid.

Also in February, Last Energy announced plans to develop 30 micro-nuclear reactors at a 200-acre site about halfway between Lubbock and Fort Worth.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings